SILVER SPRING, MD, June 16, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, JD, and its Chief Operating Officer, Gerald W. Crabtree, Ph.D., have scheduled meetings to showcase PharmaCyte Biotech’s technology and treatments for cancer and diabetes to the media, large biotechnology firms and institutional investors at the 2015 BIO International Convention being held June 15-18, 2015, at the Philadelphia Convention Center in Philadelphia, Pennsylvania.
On Monday, June 15, 2015, PharmaCyte’s executives sat for an interview with Dr. Moira Gunn, the host of Tech Nation and BioTech Nation, which both air in such venues as National Public Radio’s (NPR) 24-hour Program stream, NPR’s SIRIUS Satellite Radio channel “NPR Now,” and internationally to 177 countries via American Forces Radio International. In addition to meeting with BioTech Nation Radio, PharmaCyte Biotech’s story was presented to representatives of the biotechnology publications BioWorld, BioCentury and BioSpace.
Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte Biotech, stated, “Both Dr. Crabtree and I are extremely busy as this year’s convention opens up here in Philadelphia, Pennsylvania, with one meeting after another. We have had the opportunity to sit down for a number of media interviews, including one with Dr. Moira Gunn at BioTech Nation that will introduce her audience to our treatments for pancreatic cancer and diabetes when it airs. We have been fortunate to have so much interest in what we’re doing at PharmaCyte Biotech from other biotechnology firms and institutional investors alike. These are all great introductions that put the PharmaCyte Biotech story front and center for the world to learn more about than ever before.”
This year’s BIO International Convention is termed, “The Global Event for Biotechnology.” This Convention is the world’s largest biotechnology gathering. Over 40,000 people are expected to attend this year’s Convention. The annual BIO convention allows companies like PharmaCyte Biotech the opportunity to interact with influential decision makers and high-level executives, who come to BIO to discover new “players” in the biotechnology sector, evaluate emerging technologies and even form new partnerships.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.
PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the
benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: [email protected]
